 | • レポートコード：MRC2305A083 • 出版社/出版日：Transparency Market Research / 2023年3月27日 • レポート形態：英文、PDF、183ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートによると、世界のバソプレシン拮抗薬市場規模が、2023年の17億ドルから2031年に27億ドルとなり、予測期間中に年平均4.9%で成長すると推測されています。本レポートは、バソプレシン拮抗薬の世界市場について徹底的に分析・調査を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬剤別（バプリゾール、トルバプタン）分析、用途別（中枢性尿崩症、腎性尿崩症、その他）分析、流通チャネル別（小売薬局、病院薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の項目を整理しています。また、Otsuka、Cumberland Pharmaceuticals、Mayo Clinic、Hopital du Sacre-Coeur de Montrealなど、主要企業情報を含んでいます。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界のバソプレシン拮抗薬市場規模：薬剤別 - バプリゾールの市場規模 - トルバプタンの市場規模 ・世界のバソプレシン拮抗薬市場規模：用途別 - 中枢性尿崩症における市場規模 - 腎性尿崩症における市場規模 - その他用途における市場規模 ・世界のバソプレシン拮抗薬市場規模：流通チャネル別 - 小売薬局チャネルの市場規模 - 病院薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界のバソプレシン拮抗薬市場規模：地域別 - 北米のバソプレシン拮抗薬市場規模 - ヨーロッパのバソプレシン拮抗薬市場規模 - アジア太平洋のバソプレシン拮抗薬市場規模 - 中南米のバソプレシン拮抗薬市場規模 - 中東・アフリカのバソプレシン拮抗薬市場規模 ・競争状況 |
Vasopressin Antagonists Market – Scope of Report
TMR’s report on the global vasopressin antagonists market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global vasopressin antagonists market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global vasopressin antagonists market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the vasopressin antagonists market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global vasopressin antagonists market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global vasopressin antagonists market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global vasopressin antagonists market.
The report delves into the competitive landscape of the global vasopressin antagonists market. Key players operating in the global vasopressin antagonists market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global vasopressin antagonists market profiled in this report.
Key Questions Answered in Global Vasopressin Antagonists Market Report
• What is the sales/revenue generated by vasopressin antagonists across all regions during the forecast period?
• What are the opportunities in the global vasopressin antagonists market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Vasopressin Antagonists Market – Research Objectives and Research Approach
The comprehensive report on the global vasopressin antagonists market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global vasopressin antagonists market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global vasopressin antagonists market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Vasopressin Antagonists Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Vasopressin Antagonists Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Incidence and Prevalence
5.3. Regulatory Approval
5.4. COVID-19 Impact Analysis
6. Global Vasopressin Antagonists Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Vaprisol
6.3.2. Tolvaptan
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Vasopressin Antagonists Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Central Diabetes Insipidus
7.3.2. Nephrogenic Diabetes Insipidus
7.3.3. Other Applications
7.4. Market Attractiveness Analysis, by Application
8. Global Vasopressin Antagonists Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Retail Pharmacies
8.3.2. Hospital Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Vasopressin Antagonists Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Vasopressin Antagonists Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Type, 2017–2031
10.2.1. Vaprisol
10.2.2. Tolvaptan
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Central Diabetes Insipidus
10.3.2. Nephrogenic Diabetes Insipidus
10.3.3. Other Applications
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Retail Pharmacies
10.4.2. Hospital Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Type
10.6.2. By Application
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Vasopressin Antagonists Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017–2031
11.2.1. Vaprisol
11.2.2. Tolvaptan
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Central Diabetes Insipidus
11.3.2. Nephrogenic Diabetes Insipidus
11.3.3. Other Applications
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Retail Pharmacies
11.4.2. Hospital Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Type
11.6.2. By Application
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Vasopressin Antagonists Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2031
12.2.1. Vaprisol
12.2.2. Tolvaptan
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Central Diabetes Insipidus
12.3.2. Nephrogenic Diabetes Insipidus
12.3.3. Other Applications
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Retail Pharmacies
12.4.2. Hospital Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Type
12.6.2. By Application
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Vasopressin Antagonists Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017–2031
13.2.1. Vaprisol
13.2.2. Tolvaptan
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Central Diabetes Insipidus
13.3.2. Nephrogenic Diabetes Insipidus
13.3.3. Other Applications
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Retail Pharmacies
13.4.2. Hospital Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Type
13.6.2. By Application
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Vasopressin Antagonists Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2017–2031
14.2.1. Vaprisol
14.2.2. Tolvaptan
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Central Diabetes Insipidus
14.3.2. Nephrogenic Diabetes Insipidus
14.3.3. Other Applications
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Retail Pharmacies
14.4.2. Hospital Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Type
14.6.2. By Application
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2022
15.3. Company Profiles
15.3.1. Otsuka
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Test Drug Type Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Cumberland Pharmaceuticals
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Test Drug Type Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Mayo Clinic
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Test Drug Type Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Hopital du Sacre-Coeur de Montreal
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Test Drug Type Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview